Invitro Capital
Emerging managerBuilt from this firm's Form D filings. The firm files no SEC adviser report.
- Website
- https://invitrocapital.com
- HQ
- CA
InVitro Capital is a holding company that acquires, builds, and scales AI companies transforming healthcare. Its portfolio spans HealthTech, FinTech, and HR. Its first fund is reported to have a TVPI of 15.9x for its 2021 fund, and Mario Karras played a pivotal role in raising that inaugural fund. Portfolio companies include Curenta, Östa, and AllCare.ai.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Seed, Growth | Not enough dated deals |
| Sectors | Fintech, Healthtech, HR and future of work | Not enough dated deals |
| Regions | Not stated | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| InVitro Capital Fund I LP InVitro Capital builds and funds AI companies from idea to exit, targeting fragmented, labor-intensive markets in healthcare, HealthTech, FinTech, AdTech and HR. It acquires, builds and scales portfolio companies with hands-on operational support and long-term ownership. Inferred from the firm's website | 2024 | $3.55M to $50M (Form D) | Open, writing first checks |
03 · People across funds
- Amir Barsoum
InVitro Capital Fund I LP (Named on Form D)
- Melinda Schober, VP of Marketing & Investor Relations
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://invitrocapital.com
- https://invitrocapital.com/companies/
- https://invitrocapital.com/newsinsights/thought-leadership/venture-builders-the-next-generation-of-private-market-investments/
- https://invitrocapital.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026